Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-07-04 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases, including dates, prices, and quantities. The document also includes confirmations regarding compliance with listing rules and regulatory requirements. The content is focused on share repurchase activities and changes in capital structure rather than financial results, management changes, or other report types. Therefore, this document fits the category of a report on share repurchase or capital changes.
2024-07-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2024. It details movements in issued shares, treasury shares, share repurchases, cancellations, and other share capital changes for Simcere Pharmaceutical Group Limited. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital movements and related confirmations. It does not contain financial statements, earnings data, management discussion, or audit information. It is a regulatory filing related to share capital movements and disclosures under exchange rules, not a financial report or announcement of voting results. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and details repurchase transactions, including dates, prices, and quantities of shares repurchased. The document includes confirmations about compliance with listing rules and regulatory requirements. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchases and changes in capital structure. This matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length is substantial and contains detailed transactional data, not just an announcement or certification, so it is not RNS or RPA. Therefore, the correct classification is POS with high confidence.
2024-07-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases, including dates, prices, and quantities. The document is a regulatory disclosure about share repurchase activities and changes in share capital, not a financial report or earnings release. It is not a report publication announcement or certification but a formal disclosure of share transactions by the issuer. This fits the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length (13,574 characters) supports it being a full disclosure rather than a brief announcement. Therefore, the correct classification is POS with high confidence.
2024-07-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares for Simcere Pharmaceutical Group Limited. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and details share repurchase transactions, including dates, prices, and quantities. The document is a regulatory disclosure about share repurchases and changes in capital structure rather than a financial report or earnings announcement. It is not a full financial report, earnings release, or management discussion but a formal notification of share repurchase activity. This fits the definition of a 'Transaction in Own Shares' filing, which covers company buybacks or sales of its own shares.
2024-06-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares for Simcere Pharmaceutical Group Limited. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases, including dates, prices, and quantities. The document includes confirmations of compliance with listing rules and regulatory requirements. It is a regulatory disclosure about share repurchase activities rather than a financial report, earnings release, or management discussion. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-06-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.